Skip to main content
SpringerLink
Log in

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Autologous stem cell transplantation (ASCT) is considered as an attractive treatment option for young mantle cell lymphoma (MCL) patients. This retrospective SFGM-TC study analyzed the outcome of 500 MCL patients treated with ASCT and investigated parameters that may modify the outcome of patients who proceeded to ASCT upfront (n = 396). For all patients, median age at ASCT was 56 years (range, 26–71). Median follow-up was 34 months. Three-year progression free survival (PFS) and overall survival (OS) were 63.5 % [95 % CI, 58.7–68.6 %] and 79.5 % [95 % CI, 75.3–83.4 %], respectively. Median time from ASCT to relapse was 22 months (range, 0–136 m). For patients transplanted upfront and in multivariate analysis, age (HR = 2 [1.2–3.4], p = .01, and HR = 2.3 [1.2–4.5], p = .01), disease status at time of ASCT (HR = 1.7 [1.1–2.6], p = .01 and HR = 1.8 [1.1–3.1], p = .03), and use of rituximab (HR = 0.5 [0.3–0.8], p = .002 and HR = 0.5 [0.3–0.9], p = .01) were statistically predictive for both PFS and OS. Also, first line treatment including anthracycline and high-dose cytarabine followed by ASCT conditioned with TAM improved PFS. To conclude, this study suggests that ASCT in MCL can provide a high response rate but may not be sufficient to cure MCL even when ASCT is performed upfront, highlighting the need for innovative approaches before ASCT, aiming to increase complete response rate, and after ASCT, to maintain response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jares P, Campo E (2008) Advances in the understanding of mantle cell lymphoma. Br J Haematol 142:149–165. doi:10.1111/j.1365-2141.2008.07124.x

    Article  CAS  PubMed  Google Scholar 

  2. Pérez-Galán P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26–38. doi:10.1182/blood-2010-04-189977

    Article  PubMed  Google Scholar 

  3. Zhou Y, Wang H, Fang W et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791–798. doi:10.1002/cncr.23608

    Article  PubMed  Google Scholar 

  4. Harel S, Delarue R, Ribrag V et al (2011) Treatment of younger patients with mantle cell lymphoma. Semin Hematol 48:194–207. doi:10.1053/j.seminhematol.2011.06.002

    Article  CAS  PubMed  Google Scholar 

  5. Kluin-Nelemans HC, Doorduijn JK (2011) Treatment of elderly patients with mantle cell lymphoma. Semin Hematol 48:208–213. doi:10.1053/j.seminhematol.2011.03.008

    Article  CAS  PubMed  Google Scholar 

  6. Herrmann A, Hoster E, Zwingers T et al (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511–518. doi:10.1200/JCO.2008.16.8435

    Article  PubMed  Google Scholar 

  7. Dreyling M, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677–2684. doi:10.1182/blood-2004-10-3883

    Article  CAS  PubMed  Google Scholar 

  8. Damon LE, Johnson JL, Niedzwiecki D et al (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle cell lymphoma: CALGB 59909. J Clin Oncol 27:6101–6108. doi:10.1200/JCO.2009.22.2554

    Article  CAS  PubMed  Google Scholar 

  9. Geisler CH, Kolstad A, Laurell A et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687–2693. doi:10.1182/blood-2008-03-147025

    Article  CAS  PubMed  Google Scholar 

  10. Khouri IF, Romaguera J, Kantarjian H et al (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803–3809

    CAS  PubMed  Google Scholar 

  11. Khouri IF, Saliba RM, Okoroji G-J et al (2003) Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 98:2630–2635. doi:10.1002/cncr.11838

    Article  PubMed  Google Scholar 

  12. Lefrère F, Delmer A, Levy V et al (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89:1275–1276

    PubMed  Google Scholar 

  13. Thieblemont C, Antal D, Lacotte-Thierry L et al (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 104:1434–1441. doi:10.1002/cncr.21313

    Article  CAS  PubMed  Google Scholar 

  14. Vigouroux S, Gaillard F, Moreau P et al (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 90:1580–1582

    CAS  PubMed  Google Scholar 

  15. Gianni AM, Magni M, Martelli M et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749–755. doi:10.1182/blood-2002-08-2476

    Article  CAS  PubMed  Google Scholar 

  16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987–994. doi:10.1056/NEJM199309303291402

    Article  Google Scholar 

  17. Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558–565. doi:10.1182/blood-2007-06-095331

    Article  CAS  PubMed  Google Scholar 

  18. Peterlin P, Leux C, Gastinne T et al (2012) Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation 94:295–301. doi:10.1097/TP.0b013e318256dcba

    Article  PubMed  Google Scholar 

  19. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244

    CAS  PubMed  Google Scholar 

  20. Budde LE, Guthrie KA, Till BG et al (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023–3029. doi:10.1200/JCO.2010.33.7055

    Article  PubMed  Google Scholar 

  21. Lenz G, Dreyling M, Hoster E et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984–1992. doi:10.1200/JCO.2005.08.133

    Article  CAS  PubMed  Google Scholar 

  22. Schulz H, Bohlius JF, Trelle S et al (2007) Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 99:706–714. doi:10.1093/jnci/djk152

    Article  CAS  PubMed  Google Scholar 

  23. Griffiths R, Mikhael J, Gleeson M et al (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 118:4808–4816. doi:10.1182/blood-2011-04-348367

    Article  CAS  PubMed  Google Scholar 

  24. Hermine O, Hoster E, Walewski J et al (2012) Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). ASH Annu Meet Abstr 120:151

    Google Scholar 

  25. Pott C, Hoster E, Delfau-Larue M-H et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215–3223. doi:10.1182/blood-2009-06-230250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Liu H, Johnson JL, Koval G et al (2012) Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica 97:579–585. doi:10.3324/haematol.2011.050203

    Article  CAS  PubMed  Google Scholar 

  27. Pott C, Schrader C, Gesk S et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271–2278. doi:10.1182/blood-2005-07-2845

    Article  CAS  PubMed  Google Scholar 

  28. Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42–51. doi:10.1016/S0140-6736(10)62175-7

    Article  CAS  PubMed  Google Scholar 

  29. Van Oers MHJ, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295–3301. doi:10.1182/blood-2006-05-021113

    Article  PubMed  Google Scholar 

  30. Forstpointner R, Unterhalt M, Dreyling M et al (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003–4008. doi:10.1182/blood-2006-04-016725

    Article  CAS  PubMed  Google Scholar 

  31. Ghielmini M, Schmitz S-FH, Cogliatti S et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705–711. doi:10.1200/JCO.2005.04.164

    Article  CAS  PubMed  Google Scholar 

  32. Kluin-Nelemans HC, Hoster E, Hermine O et al (2012) Treatment of older patients with mantle cell lymphoma. N Engl J Med 367:520–531. doi:10.1056/NEJMoa1200920

    Article  CAS  PubMed  Google Scholar 

  33. Le Gouill S, Callanan M, Macintyre E et al (2012) Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa Trial, a Lysa Study. ASH Annu Meet Abstr 120:152

    Google Scholar 

  34. Andersen NS, Pedersen LB, Laurell A et al (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27:4365–4370. doi:10.1200/JCO.2008.21.3116

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

SLG is supported by a grant from Pays de La Loire, France and the PAIR-lymphoma program (INCa). The authors thank Nicole Raus for her help and support.

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital, Nantes, France

    Cyrille Touzeau & Steven Le Gouill

  2. INSERM UMR 892, University of Nantes, Nantes, France

    Cyrille Touzeau & Steven Le Gouill

  3. Clinical Investigation Unit, University Hospital, Nantes, France

    Cyrille Touzeau & Steven Le Gouill

  4. Department of Epidemiology and Biostatistics, University Hospital, Nantes, France

    Christophe Leux

  5. Institut Paoli Calmette, Marseille, France

    Reda Bouabdallah

  6. Department of Hematology, University Hospital, Toulouse, France

    Murielle Roussel

  7. Department of Hematology, University Hospital Necker, Paris, France

    Richard Delarue & Olivier Hermine

  8. Department of Hematology, University Hospital, Bordeaux, France

    Krimo Bouabdallah & Noel Milpied

  9. Department of Hematology, University Hospital Saint Louis, Paris, France

    Catherine Thieblemont

  10. Inserm U728, University of Paris, Paris, France

    Catherine Thieblemont

  11. Department of Hematology, University Hospital, Clermont-Ferrand, France

    Victoria Cacheux

  12. Department of Hematology, University Hospital, Montpellier, France

    Guillaume Cartron

  13. Department of Hematology, University Hospital Pitié-Salpêtrière, Paris, France

    Laetitia Compain

  14. Department of Hematology, University Hospital of Tours, Tours, France

    Emmanuel Gyan

  15. CIC INSERM U202, CNRS UMR 7292, University of Tours, Tours, France

    Emmanuel Gyan

  16. Department of Hematology, University Hospital of Lille, Lille, France

    Franck Morschhauser

  17. Department of Hematology, University Hospital of Dijon, Dijon, France

    Olivier Casasnovas

  18. Department of Hematology, University Hospital of Angers, Angers, France

    Marie-Pierre Moles

  19. Department of Hematology, University Hospital, Lyon, France

    Anne-Sophie Michallet

  20. Department of Hematology, University Hospital, Grenoble, France

    Remy Gressin

  21. INSERM, U 823, University of Grenoble, Grenoble, France

    Remy Gressin

  22. Department of Hematology, University Hospital, Amiens, France

    Gandhi Damaj

  23. Department of Hematology, Saint Vincent Hospital, Lille, France

    Christian Rose

  24. Department of Hematology, University Hospital, Nice, France

    Anne Sirvent

  25. Department of Hematology, University Hospital Saint Antoine, Paris, France

    Mohamad Mohty

  26. Centre d’investigation Clinique en Cancérologie (CI2C), University Hospital of Nantes, Nantes, France

    Steven Le Gouill

  27. Service d’Hématologie Clinique, CHU de Nantes, Place Alexis Ricordeau, 44093, Nantes Cedex 1, France

    Steven Le Gouill

Authors
  1. Cyrille Touzeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Leux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reda Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murielle Roussel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard Delarue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Krimo Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Catherine Thieblemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Victoria Cacheux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guillaume Cartron
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Laetitia Compain
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Emmanuel Gyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Franck Morschhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Olivier Casasnovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Marie-Pierre Moles
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Anne-Sophie Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Remy Gressin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Gandhi Damaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Christian Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Anne Sirvent
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Olivier Hermine
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Noel Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Steven Le Gouill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Le Gouill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Touzeau, C., Leux, C., Bouabdallah, R. et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 93, 233–242 (2014). https://doi.org/10.1007/s00277-013-1860-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1860-8

Keywords

Search

Navigation